Author
Listed:
- Saroor A. Patel
(University of Cambridge, Hutchison/MRC Research Centre, Cambridge Biomedical Campus
Wellcome Sanger Institute)
- Shoko Hirosue
(University of Cambridge, Hutchison/MRC Research Centre, Cambridge Biomedical Campus)
- Paulo Rodrigues
(University of Cambridge, Hutchison/MRC Research Centre, Cambridge Biomedical Campus)
- Erika Vojtasova
(University of Cambridge, Hutchison/MRC Research Centre, Cambridge Biomedical Campus)
- Emma K. Richardson
(University of Cambridge, Hutchison/MRC Research Centre, Cambridge Biomedical Campus
National Cancer Centre Singapore)
- Jianfeng Ge
(University of Cambridge, Hutchison/MRC Research Centre, Cambridge Biomedical Campus)
- Saiful E. Syafruddin
(University of Cambridge, Hutchison/MRC Research Centre, Cambridge Biomedical Campus
Universiti Kebangsaan Malaysia, Jalan Yaacob Latiff)
- Alyson Speed
(University of Cambridge, Hutchison/MRC Research Centre, Cambridge Biomedical Campus)
- Evangelia K. Papachristou
(University of Cambridge, Robinson Way)
- David Baker
(Norwich Research Park)
- David Clarke
(Cambridge University Hospitals NHS Foundation Trust)
- Stephenie Purvis
(Cambridge University Hospitals NHS Foundation Trust)
- Ludovic Wesolowski
(University of Cambridge, Hutchison/MRC Research Centre, Cambridge Biomedical Campus)
- Anna Dyas
(University of Cambridge, Hutchison/MRC Research Centre, Cambridge Biomedical Campus)
- Leticia Castillon
(University of Cambridge, Hutchison/MRC Research Centre, Cambridge Biomedical Campus
University of Helsinki)
- Veronica Caraffini
(University of Cambridge, Hutchison/MRC Research Centre, Cambridge Biomedical Campus)
- Dóra Bihary
(University of Cambridge, Hutchison/MRC Research Centre, Cambridge Biomedical Campus)
- Cissy Yong
(University of Cambridge, Cambridge Biomedical Campus
Cambridge University Hospitals NHS Foundation Trust)
- David J. Harrison
(University of St Andrews)
- Grant D. Stewart
(University of Cambridge, Cambridge Biomedical Campus)
- Mitchell J. Machiela
(National Cancer Institute)
- Mark P. Purdue
(National Cancer Institute)
- Stephen J. Chanock
(National Cancer Institute)
- Anne Y. Warren
(Cambridge University Hospitals NHS Foundation Trust)
- Shamith A. Samarajiwa
(University of Cambridge, Hutchison/MRC Research Centre, Cambridge Biomedical Campus)
- Jason S. Carroll
(University of Cambridge, Robinson Way)
- Sakari Vanharanta
(University of Cambridge, Hutchison/MRC Research Centre, Cambridge Biomedical Campus
University of Helsinki
University of Helsinki)
Abstract
Large-scale human genetic data1–3 have shown that cancer mutations display strong tissue-selectivity, but how this selectivity arises remains unclear. Here, using experimental models, functional genomics and analyses of patient samples, we demonstrate that the lineage transcription factor paired box 8 (PAX8) is required for oncogenic signalling by two common genetic alterations that cause clear cell renal cell carcinoma (ccRCC) in humans: the germline variant rs7948643 at 11q13.3 and somatic inactivation of the von Hippel-Lindau tumour suppressor (VHL)4–6. VHL loss, which is observed in about 90% of ccRCCs, can lead to hypoxia-inducible factor 2α (HIF2A) stabilization6,7. We show that HIF2A is preferentially recruited to PAX8-bound transcriptional enhancers, including a pro-tumorigenic cyclin D1 (CCND1) enhancer that is controlled by PAX8 and HIF2A. The ccRCC-protective allele C at rs7948643 inhibits PAX8 binding at this enhancer and downstream activation of CCND1 expression. Co-option of a PAX8-dependent physiological programme that supports the proliferation of normal renal epithelial cells is also required for MYC expression from the ccRCC metastasis-associated amplicons at 8q21.3-q24.3 (ref. 8). These results demonstrate that transcriptional lineage factors are essential for oncogenic signalling and that they mediate tissue-specific cancer risk associated with somatic and inherited genetic variants.
Suggested Citation
Saroor A. Patel & Shoko Hirosue & Paulo Rodrigues & Erika Vojtasova & Emma K. Richardson & Jianfeng Ge & Saiful E. Syafruddin & Alyson Speed & Evangelia K. Papachristou & David Baker & David Clarke & , 2022.
"The renal lineage factor PAX8 controls oncogenic signalling in kidney cancer,"
Nature, Nature, vol. 606(7916), pages 999-1006, June.
Handle:
RePEc:nat:nature:v:606:y:2022:i:7916:d:10.1038_s41586-022-04809-8
DOI: 10.1038/s41586-022-04809-8
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:606:y:2022:i:7916:d:10.1038_s41586-022-04809-8. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.